Mountain View Pharmaceuticals, Inc.
Development of PEG-Uricase for Treatment of Intractable Gout and — US partner. Israeli partner: Savient Pharmaceuticals Inc. (Formerly: Bio-Technology General Ltd.) (Rehovot (Tel Aviv & Central)). Sector: Life Sciences, Medical Devices. The U.S. Food and Drug Administration has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients that are refractory to conventional therapy. The drug was developed by Mountain View Pharmaceuticals, and Bio-technology General (acquired by Ferring Pharmaceuticals in 2005) with a grant from the BIRD Foundation